OncoTherapy Science (4564) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Revenue increased, primarily due to growth in the cancer precision medicine-related business; however, the Company remains in an operating loss position as research and development investment continues to precede revenue generation. Revenue was ¥5.97B (+6.1% YoY), while Operating Income was ¥-6.94B, improving by +0.6% from ¥-6.98B in the previous year. Ordinary Income was ¥-7.20B (-0.6% YoY), and Net Income was ¥-7.83B (-9.2% YoY), indicating a widening net loss. The deterioration in Net Income was attributable to extraordinary losses, including an impairment loss of ¥0.62B, which exceeded the improvement in operating results.

Factors Affecting Earnings

【Revenue】Revenue was ¥5.97B, an increase of +6.1% YoY. The core cancer precision medicine-related business grew to ¥5.95B (+6.2% YoY), accounting for nearly all consolidated Revenue. Meanwhile, the business related to “research and development of pharmaceuticals” contracted to ¥0.02B (-21.5% YoY), further increasing the Company’s reliance on the cancer precision medicine-related business for earnings.

【Profit and Loss】Cost of sales decreased to ¥5.80B (-1.2% YoY), resulting in an improved gross margin. SG&A expenses were ¥3.25B (+4.1% YoY), while R&D expenses were ¥3.87B, equivalent to 64.8% of Revenue and up from 64.3% in the previous year, continuing to account for the central component of the cost structure. The Operating Loss narrowed slightly to ¥6.94B YoY, and the Operating Margin improved to -116.2% from -124.0% in the previous year, but remained far from profitability. Ordinary Loss was ¥7.20B, broadly in line with the previous year, while Net Loss widened to ¥7.83B due to extraordinary losses, including an impairment loss of ¥0.62B. The results represent higher revenue but lower earnings, with a slight improvement in operating results offset by deterioration in net results.

Segment Analysis

The cancer precision medicine-related business generated external Revenue of ¥5.95B (+6.2% YoY) and a segment loss of ¥0.34B, a 53.3% reduction from ¥0.74B in the previous year, making it the central contributor to the improvement in consolidated earnings. Meanwhile, the business related to “research and development of pharmaceuticals” generated external Revenue of ¥0.02B (-21.5% YoY), while its segment loss widened by +7.0% YoY to ¥3.84B. Corporate expenses not allocated to individual segments were ¥2.76B (+4.1% YoY), making the containment of corporate expenses, in addition to revenue growth in the core business, an important issue for improving consolidated earnings.

Key Financial Indicators

【Profitability】The Operating Margin was -116.2%, an improvement of approximately 780bp from -124.0% in the previous year, while the Net Profit Margin was -131.2%, deteriorating from -127.4% in the previous year. The gross margin improved due to lower costs, but R&D expenses accounted for 64.8% of Revenue, leaving the Company far from profitability.【Cash Flow Quality】Net Loss was ¥7.83B compared with Ordinary Loss of ¥7.20B; the ¥0.64B difference was primarily attributable to the impairment loss, indicating that non-recurring factors expanded the loss.【Investment Efficiency】Annualized ROE was -48.9%, while the total asset turnover ratio remained low, indicating that the Company has not yet generated Revenue commensurate with its asset base accumulated through capital strengthening.【Financial Soundness】The Equity Ratio was 86.2%, and cash and deposits of ¥21.9B accounted for the majority of total assets. The debt-to-equity ratio was low and the financial foundation was strong; however, accumulated retained earnings stood at a substantially negative ¥-276.9B.

Cash Flow Analysis

Although the cash flow statement has not been disclosed, funding trends can be assessed based on changes in the balance sheet. Cash and deposits increased substantially to ¥21.9B from ¥8.3B in the same period of the previous year. Capital stock increased from ¥0.5B to ¥11.5B, while capital surplus also increased, suggesting that cash inflows from capital strengthening were the primary cause of the increase in cash. Net assets expanded to ¥21.4B, and the Equity Ratio reached 86.2%. However, the Company continues to record Operating Loss and Net Loss, and its business activities themselves have a cash-consuming structure. Accordingly, future cash balances will depend on the pace of losses and whether additional funding is raised.

Earnings Quality

Ordinary Loss was ¥7.20B compared with an Operating Loss of ¥6.94B, with non-operating expenses of ¥0.26B, including interest expenses of ¥0.01B and foreign exchange losses of ¥0.01B, slightly increasing the loss. Non-operating income was virtually zero, and there were no factors supporting earnings. Extraordinary losses were ¥0.62B, all of which consisted of impairment losses. After deducting extraordinary income of ¥0.01B, Net Loss exceeded Ordinary Loss by ¥0.64B. Therefore, part of the Net Loss for the period was attributable to the temporary factor of impairment; however, even excluding this factor, the Ordinary Loss remained substantial at ¥7.20B, making the improvement of underlying earnings power an ongoing challenge.

Shareholder Returns

The Full-Year dividend forecast is ¥0.00 per share, and the Company continues to pay no dividend. The Company recorded a Net Loss of ¥7.83B on a cumulative Q3 basis, making the Payout Ratio meaningless for analytical purposes. Cash on hand of ¥21.9B appears to be retained for R&D investment and business operating funds rather than shareholder returns.

Risk Factors

1. Revenue concentration risk: External Revenue of ¥5.95B from the cancer precision medicine-related business accounts for nearly all consolidated Revenue, meaning that demand trends and competitive conditions in this business, as well as changes in the medical reimbursement system, will directly affect performance.

2. Ongoing cash consumption risk: The Operating Loss of ¥6.94B and Net Loss of ¥7.83B exceed Revenue of ¥5.97B, and the cash balance of ¥21.9B depends on the future pace of losses and the need for additional capital raising.

3. Impairment risk: The Company recorded an impairment loss of ¥0.62B during the period, requiring ongoing reviews of the recoverability of R&D-related assets and operating assets.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

The loss margin is smaller than the industry median, and profitability ranks relatively favorably within the industry.

Growth and Capital Efficiency

While many peers experienced revenue declines, the Company secured revenue growth, placing its growth profile among the stronger performers in the industry.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Revenue growth in the cancer precision medicine-related business and the 53.3% YoY reduction in its segment loss have been the central drivers of the improvement in consolidated earnings.

2. R&D expenses reached 64.8% of Revenue, and the cost structure continues to reflect the structural losses characteristic of an R&D-oriented company. The deterioration in Net Income was attributable to an impairment loss of ¥0.62B that exceeded the improvement in operating results.

3. Although the financial foundation is strong, with cash and deposits of ¥21.9B and an Equity Ratio of 86.2%, accumulated retained earnings were ¥-276.9B. Future progress toward commercialization and trends in financing activities will therefore remain key areas of focus.

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility and, where necessary, after consulting with a professional.

---End of Report---